SCHD ETF Outperforms with Strong Returns, Attracts Investor Interest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 30 minutes ago
0mins
Source: Fool
- Strong Start to the Year: As of Tuesday, the S&P 500 is up 7%, with a remarkable 15% increase since March 30, reflecting growing investor confidence in economic recovery and heightened market interest.
- Impressive SCHD Returns: The Schwab U.S. Dividend Equity ETF (SCHD) has risen over 15% year-to-date, with its appeal strengthening as investors seek high-quality dividend stocks, making it a top choice for portfolio diversification.
- Portfolio Stability: SCHD's holdings must meet strict criteria, including 10 consecutive years of dividend increases and solid debt ratios, ensuring stable returns during economic uncertainty, which attracts risk-averse investors.
- Long-Term Investment Value: Since its inception in October 2011, SCHD has averaged 13.1% annual total returns; while past performance does not guarantee future results, its consistent income and low expense ratio (0.06%) position it as an ideal option for long-term investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 111.280
Low
95.00
Averages
119.53
High
139.00
Current: 111.280
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SCHD ETF Outperforms with Strong Returns, Attracts Investor Interest
- Strong Start to the Year: As of Tuesday, the S&P 500 is up 7%, with a remarkable 15% increase since March 30, reflecting growing investor confidence in economic recovery and heightened market interest.
- Impressive SCHD Returns: The Schwab U.S. Dividend Equity ETF (SCHD) has risen over 15% year-to-date, with its appeal strengthening as investors seek high-quality dividend stocks, making it a top choice for portfolio diversification.
- Portfolio Stability: SCHD's holdings must meet strict criteria, including 10 consecutive years of dividend increases and solid debt ratios, ensuring stable returns during economic uncertainty, which attracts risk-averse investors.
- Long-Term Investment Value: Since its inception in October 2011, SCHD has averaged 13.1% annual total returns; while past performance does not guarantee future results, its consistent income and low expense ratio (0.06%) position it as an ideal option for long-term investors.
See More
European Stocks Rebound as Siemens Launches €6 Billion Buyback Program
- Siemens Buyback Program: Siemens has announced a €6 billion ($7.04 billion) share buyback program covering the next five years, reflecting the company's confidence in future performance, which is expected to enhance shareholder returns and boost market sentiment.
- Earnings Beat Expectations: Siemens reported a net profit of €2.03 billion for the first quarter, exceeding market expectations, indicating strong performance in the automation sector, which could drive the company's stock price higher and attract more investor interest.
- European Market Rebound: The UK FTSE index is expected to rise by 0.6%, Germany's DAX by 0.5%, France's CAC 40 by 0.6%, and Italy's FTSE MIB by 0.7%, reflecting optimistic sentiment about economic recovery, which may stimulate investor confidence.
- Global Market Focus: Global investors are keenly watching the upcoming meeting between Trump and Xi, where trade and the Iran situation will be discussed, potentially impacting market sentiment significantly, especially ahead of the U.S. inflation data release.
See More
FDA Commissioner Marty Makary Ousted Amid Controversies
- Leadership Change at FDA: Marty Makary's departure on Tuesday, with Deputy Commissioner Kyle Diamantas stepping in as acting commissioner, reflects growing dissatisfaction within the Trump administration regarding the FDA's chaotic management, potentially impacting the agency's policy direction and industry trust.
- Industry Reactions: Under Makary's tenure, the FDA faced significant controversies, particularly with Replimune criticizing the agency for rejecting its melanoma treatment, which led to an over 8% rise in its stock on Tuesday, indicating market sensitivity to FDA decisions.
- Regulatory Decision Controversies: Makary's term has been marred by accusations of conflicts of interest in FDA regulatory decisions, and the use of “expert panels” often contradicting mainstream medical opinions, which may undermine public trust in the agency.
- Impact on Other Companies: Companies like Regenxbio and Moderna also faced FDA rejections during Makary's leadership, affecting their product approval timelines and potentially leading to negative implications for future R&D investment decisions.
See More
Equity Markets Steady Amid Uncertainty; Quality Dividend Stocks Attract Investors
- Market Performance: The S&P 500 has risen 7% year-to-date, demonstrating resilience amid economic uncertainty and geopolitical instability, although fresh challenges may still arise in the future.
- Amgen's Outlook: Despite facing biosimilar competition, Amgen is expected to see revenue growth in 2026, supported by a diverse product lineup and a strong pipeline, with 16 brands achieving double-digit growth in Q1.
- Merck's Strategy: Merck's key drug Keytruda will lose patent protection in 2028, but the approval of a subcutaneous version is expected to retain patients, while new drugs like Winrevair and Capvaxive are performing well in the market.
- Dividend Appeal: Both Amgen and Merck offer around a 3% dividend yield, significantly higher than the S&P 500's average of 1.1%, and both companies have notably increased their dividends over the past decade, attracting income-seeking investors.
See More
Doceree Launches New System for Pharma Brand Teams
- Collaboration of Industry Leaders: Doceree's Daily Command system, co-built by 75 senior operators including 18 leaders from firms like Sanofi and Merck, signifies a fundamental shift in how pharmaceutical brand teams operate, enhancing decision-making efficiency and transparency.
- Workflow Transformation: Daily Command integrates strategies, creative, and measurement frameworks into a single platform, enabling brand teams to access and manage their work in real-time, significantly improving operational efficiency and team collaboration.
- Market Competitive Advantage: In an environment where pharmaceutical marketing budgets are under sustained pressure, agencies adopting Daily Command will be able to showcase their strategic recommendations within brand teams' daily decision-making processes, thereby increasing client retention and ensuring a competitive edge in the future.
- Open Ecosystem: The Daily Command marketplace allows agencies to integrate their proprietary tools and measurement frameworks directly into the system, ensuring that agencies' intellectual property and data partnerships remain intact, thus fostering innovation and collaboration.
See More
Merck Unveils Novel Oral PCSK9 Inhibitor Enlicitide
- Drug Development Progress: Merck announced the publication of a scalable synthesis method for its novel oral PCSK9 inhibitor, Enlicitide, in the journal Science, showcasing its potential to be the first approved oral PCSK9 inhibitor, thereby providing new treatment options for cardiovascular disease patients.
- Biocatalysis Technology Application: The study details the biocatalytic assembly of Enlicitide using a suite of enzymes, significantly enhancing synthesis efficiency and demonstrating Merck's technical prowess in biocatalysis, which could transform traditional drug synthesis methods and promote sustainability in the pharmaceutical industry.
- Market Demand Response: Enlicitide is designed to lower LDL-C levels by inhibiting interactions with LDL receptors, addressing the growing global demand for cardiovascular disease treatments, especially as cardiovascular-related mortality continues to rise, highlighting its significant market implications.
- Strategic Investment and Commitment: With over 25 years of investment in biocatalysis, Merck is dedicated to developing novel enzymes and manufacturing processes, reflecting the company's long-term commitment to innovative drug development aimed at improving global patient health outcomes.
See More
SCHD ETF Outperforms with Strong Returns, Attracts Investor Interest
- Strong Start to the Year: As of Tuesday, the S&P 500 is up 7%, with a remarkable 15% increase since March 30, reflecting growing investor confidence in economic recovery and heightened market interest.
- Impressive SCHD Returns: The Schwab U.S. Dividend Equity ETF (SCHD) has risen over 15% year-to-date, with its appeal strengthening as investors seek high-quality dividend stocks, making it a top choice for portfolio diversification.
- Portfolio Stability: SCHD's holdings must meet strict criteria, including 10 consecutive years of dividend increases and solid debt ratios, ensuring stable returns during economic uncertainty, which attracts risk-averse investors.
- Long-Term Investment Value: Since its inception in October 2011, SCHD has averaged 13.1% annual total returns; while past performance does not guarantee future results, its consistent income and low expense ratio (0.06%) position it as an ideal option for long-term investors.
See More
European Stocks Rebound as Siemens Launches €6 Billion Buyback Program
- Siemens Buyback Program: Siemens has announced a €6 billion ($7.04 billion) share buyback program covering the next five years, reflecting the company's confidence in future performance, which is expected to enhance shareholder returns and boost market sentiment.
- Earnings Beat Expectations: Siemens reported a net profit of €2.03 billion for the first quarter, exceeding market expectations, indicating strong performance in the automation sector, which could drive the company's stock price higher and attract more investor interest.
- European Market Rebound: The UK FTSE index is expected to rise by 0.6%, Germany's DAX by 0.5%, France's CAC 40 by 0.6%, and Italy's FTSE MIB by 0.7%, reflecting optimistic sentiment about economic recovery, which may stimulate investor confidence.
- Global Market Focus: Global investors are keenly watching the upcoming meeting between Trump and Xi, where trade and the Iran situation will be discussed, potentially impacting market sentiment significantly, especially ahead of the U.S. inflation data release.
See More
FDA Commissioner Marty Makary Ousted Amid Controversies
- Leadership Change at FDA: Marty Makary's departure on Tuesday, with Deputy Commissioner Kyle Diamantas stepping in as acting commissioner, reflects growing dissatisfaction within the Trump administration regarding the FDA's chaotic management, potentially impacting the agency's policy direction and industry trust.
- Industry Reactions: Under Makary's tenure, the FDA faced significant controversies, particularly with Replimune criticizing the agency for rejecting its melanoma treatment, which led to an over 8% rise in its stock on Tuesday, indicating market sensitivity to FDA decisions.
- Regulatory Decision Controversies: Makary's term has been marred by accusations of conflicts of interest in FDA regulatory decisions, and the use of “expert panels” often contradicting mainstream medical opinions, which may undermine public trust in the agency.
- Impact on Other Companies: Companies like Regenxbio and Moderna also faced FDA rejections during Makary's leadership, affecting their product approval timelines and potentially leading to negative implications for future R&D investment decisions.
See More
Equity Markets Steady Amid Uncertainty; Quality Dividend Stocks Attract Investors
- Market Performance: The S&P 500 has risen 7% year-to-date, demonstrating resilience amid economic uncertainty and geopolitical instability, although fresh challenges may still arise in the future.
- Amgen's Outlook: Despite facing biosimilar competition, Amgen is expected to see revenue growth in 2026, supported by a diverse product lineup and a strong pipeline, with 16 brands achieving double-digit growth in Q1.
- Merck's Strategy: Merck's key drug Keytruda will lose patent protection in 2028, but the approval of a subcutaneous version is expected to retain patients, while new drugs like Winrevair and Capvaxive are performing well in the market.
- Dividend Appeal: Both Amgen and Merck offer around a 3% dividend yield, significantly higher than the S&P 500's average of 1.1%, and both companies have notably increased their dividends over the past decade, attracting income-seeking investors.
See More
Doceree Launches New System for Pharma Brand Teams
- Collaboration of Industry Leaders: Doceree's Daily Command system, co-built by 75 senior operators including 18 leaders from firms like Sanofi and Merck, signifies a fundamental shift in how pharmaceutical brand teams operate, enhancing decision-making efficiency and transparency.
- Workflow Transformation: Daily Command integrates strategies, creative, and measurement frameworks into a single platform, enabling brand teams to access and manage their work in real-time, significantly improving operational efficiency and team collaboration.
- Market Competitive Advantage: In an environment where pharmaceutical marketing budgets are under sustained pressure, agencies adopting Daily Command will be able to showcase their strategic recommendations within brand teams' daily decision-making processes, thereby increasing client retention and ensuring a competitive edge in the future.
- Open Ecosystem: The Daily Command marketplace allows agencies to integrate their proprietary tools and measurement frameworks directly into the system, ensuring that agencies' intellectual property and data partnerships remain intact, thus fostering innovation and collaboration.
See More
Merck Unveils Novel Oral PCSK9 Inhibitor Enlicitide
- Drug Development Progress: Merck announced the publication of a scalable synthesis method for its novel oral PCSK9 inhibitor, Enlicitide, in the journal Science, showcasing its potential to be the first approved oral PCSK9 inhibitor, thereby providing new treatment options for cardiovascular disease patients.
- Biocatalysis Technology Application: The study details the biocatalytic assembly of Enlicitide using a suite of enzymes, significantly enhancing synthesis efficiency and demonstrating Merck's technical prowess in biocatalysis, which could transform traditional drug synthesis methods and promote sustainability in the pharmaceutical industry.
- Market Demand Response: Enlicitide is designed to lower LDL-C levels by inhibiting interactions with LDL receptors, addressing the growing global demand for cardiovascular disease treatments, especially as cardiovascular-related mortality continues to rise, highlighting its significant market implications.
- Strategic Investment and Commitment: With over 25 years of investment in biocatalysis, Merck is dedicated to developing novel enzymes and manufacturing processes, reflecting the company's long-term commitment to innovative drug development aimed at improving global patient health outcomes.
See More
